Vertical of the Week

Pharma & APIs — India's Dominant EU Export Corridor

Trade Data

India is the world's 3rd largest pharmaceutical producer and supplies approximately 40% of generic medicines consumed in the United States and 25% of those in the UK. EU pharma imports from India reached USD 4.2 billion in FY2025, primarily APIs (Active Pharmaceutical Ingredients), generic finished dose formulations, and nutraceuticals. Germany, the Netherlands, Italy, France, and Belgium are the five largest EU buyers of Indian pharma. Post-India-EU FTA, duty on pharma APIs and finished generics moves to 0% from Day 1 of implementation — making India's cost advantage even more compelling against competing origins (primarily China and Eastern Europe).

This Week's Regulatory Update

EMA (European Medicines Agency) published updated guidance on GMP inspection frequency for API manufacturers from third countries on 8 April 2026. Key change: Indian API plants with a clean inspection history (no Critical or Major observations in the past 3 years) are now eligible for a 5-year inspection cycle instead of 3-year. This reduces compliance burden for established Indian API exporters. New entrants still require a pre-approval inspection. Source: EMA/INS/GMP/897239/2025.

Opportunity This Week

A Belgian CMO (contract manufacturer) is seeking an Indian API supplier for two generic molecules: Metformin HCl and Atorvastatin Calcium. Requirements: WHO-GMP, EUGMP Annex 18, valid EU-GMP certificate, DMF filed with EMA or equivalent. Annual volume: 12 metric tonnes Metformin HCl, 800kg Atorvastatin. First qualification: stability data and analytical method transfer. If your facility produces either molecule and is WHO-GMP certified, contact both principals.

30-Week Schedule

Week 1: Pharma & APIs  |  Week 2: Engineering & Auto Parts  |  Week 3: Textiles & Leather  |  Week 4: Chemicals & Specialty  |  Week 5: Agro & Food  |  Week 6: IT Services & Digital  |  and so on through all 30 verticals. See all 30 verticals →